Mogy Joel R Investment Counsel Inc. Buys 6,400 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mogy Joel R Investment Counsel Inc. increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 8.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,724 shares of the company's stock after buying an additional 6,400 shares during the quarter. IDEXX Laboratories accounts for approximately 2.3% of Mogy Joel R Investment Counsel Inc.'s holdings, making the stock its 16th biggest position. Mogy Joel R Investment Counsel Inc. owned approximately 0.11% of IDEXX Laboratories worth $36,000,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Hurley Capital LLC purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $29,000. Rialto Wealth Management LLC purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $30,000. Colonial Trust Co SC grew its stake in IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares in the last quarter. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $38,000. Finally, Itau Unibanco Holding S.A. grew its stake in IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded down $4.22 during trading hours on Friday, hitting $522.70. 411,464 shares of the company's stock were exchanged, compared to its average volume of 650,612. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.73. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market capitalization of $42.04 billion, a price-to-earnings ratio of 48.99, a PEG ratio of 3.41 and a beta of 1.55. The company's 50-day moving average price is $473.11 and its 200-day moving average price is $444.61.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same quarter in the previous year, the firm earned $2.71 EPS. The firm's revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Stifel Nicolaus boosted their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday, May 19th. Leerink Partners upped their price target on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research note on Wednesday. Morgan Stanley upped their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average target price of $546.00.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director now owns 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.